These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 16879967)

  • 21. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.
    McClure R; Mai M; Lasho T
    Leukemia; 2006 Jan; 20(1):168-71. PubMed ID: 16270039
    [No Abstract]   [Full Text] [Related]  

  • 22. JAKing up hematopoietic proliferation.
    Shannon K; Van Etten RA
    Cancer Cell; 2005 Apr; 7(4):291-3. PubMed ID: 15837617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1.
    Lizcano JM; Göransson O; Toth R; Deak M; Morrice NA; Boudeau J; Hawley SA; Udd L; Mäkelä TP; Hardie DG; Alessi DR
    EMBO J; 2004 Feb; 23(4):833-43. PubMed ID: 14976552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LKB1-dependent signaling pathways.
    Alessi DR; Sakamoto K; Bayascas JR
    Annu Rev Biochem; 2006; 75():137-63. PubMed ID: 16756488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade.
    Hawley SA; Boudeau J; Reid JL; Mustard KJ; Udd L; Mäkelä TP; Alessi DR; Hardie DG
    J Biol; 2003; 2(4):28. PubMed ID: 14511394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.
    Lasho TL; Mesa R; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Sep; 130(5):797-9. PubMed ID: 16115143
    [No Abstract]   [Full Text] [Related]  

  • 27. Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders.
    Pesu M; O'Shea J; Hennighausen L; Silvennoinen O
    Mol Interv; 2005 Aug; 5(4):211-5. PubMed ID: 16123535
    [No Abstract]   [Full Text] [Related]  

  • 28. Methods to assess small molecule allosteric modulators of the STRAD pseudokinase.
    Qing T; Liu J; Liu F; Mitchell DC; Beresis RT; Gordan JD
    Methods Enzymol; 2022; 667():427-453. PubMed ID: 35525550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour.
    Ma W; Kantarjian H; Verstovsek S; Jilani I; Gorre M; Giles F; Cortes J; O'Brien S; Keating M; Albitar M
    Br J Haematol; 2006 Aug; 134(3):341-3. PubMed ID: 16787500
    [No Abstract]   [Full Text] [Related]  

  • 30. CSF-1 signal transduction.
    Hamilton JA
    J Leukoc Biol; 1997 Aug; 62(2):145-55. PubMed ID: 9261328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase/protein kinase B signaling pathway.
    Nguyen MH; Ho JM; Beattie BK; Barber DL
    J Biol Chem; 2001 Aug; 276(35):32704-13. PubMed ID: 11435425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. STRAD pseudokinases regulate axogenesis and LKB1 stability.
    Veleva-Rotse BO; Smart JL; Baas AF; Edmonds B; Zhao ZM; Brown A; Klug LR; Hansen K; Reilly G; Gardner AP; Subbiah K; Gaucher EA; Clevers H; Barnes AP
    Neural Dev; 2014 Mar; 9():5. PubMed ID: 24594058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK/STAT signal transduction: regulators and implication in hematological malignancies.
    Valentino L; Pierre J
    Biochem Pharmacol; 2006 Mar; 71(6):713-21. PubMed ID: 16426581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.
    Wernig G; Gonneville JR; Crowley BJ; Rodrigues MS; Reddy MM; Hudon HE; Walz C; Reiter A; Podar K; Royer Y; Constantinescu SN; Tomasson MH; Griffin JD; Gilliland DG; Sattler M
    Blood; 2008 Apr; 111(7):3751-9. PubMed ID: 18216297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inconsistencies in the association between the JAK2(V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases.
    Vannucchi AM; Guglielmelli P; Antonioli E; Mappa S; Pancrazzi A; Bogani C; Ponziani V; Bosi A
    Br J Haematol; 2006 Mar; 132(5):652-4; author reply 654. PubMed ID: 16445842
    [No Abstract]   [Full Text] [Related]  

  • 36. The V617F JAK2 mutation and the myeloproliferative disorders.
    Percy MJ; McMullin MF
    Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The kinase suppressor of Ras (KSR) modulates growth factor and Ras signaling by uncoupling Elk-1 phosphorylation from MAP kinase activation.
    Sugimoto T; Stewart S; Han M; Guan KL
    EMBO J; 1998 Mar; 17(6):1717-27. PubMed ID: 9501093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.
    Spivak JL; Moliterno AR; Silver RT
    N Engl J Med; 2006 Aug; 355(7):737; author reply 738. PubMed ID: 16914715
    [No Abstract]   [Full Text] [Related]  

  • 39. JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders.
    Rossi D; Deambrogi C; Capello D; Cerri M; Lunghi M; Parvis G; Saglio G; Gaidano G; Cilloni D
    Br J Haematol; 2006 Oct; 135(2):267-8. PubMed ID: 16956348
    [No Abstract]   [Full Text] [Related]  

  • 40. A novel MPL point mutation resulting in thrombopoietin-independent activation.
    Abe M; Suzuki K; Inagaki O; Sassa S; Shikama H
    Leukemia; 2002 Aug; 16(8):1500-6. PubMed ID: 12145691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.